Impact of beta-glucan on the faecal microbiota of polypectomized patients: A pilot study

dc.contributor.author	Turunen, K	en
dc.contributor.author	Tsouvelakidou, E	en
dc.contributor.author	Nomikos, T	en
dc.contributor.author	Mountzouris, KC	en
dc.contributor.author	Karamanolis, D	en
dc.contributor.author	Triantafillidis, J	en
dc.contributor.author	Kyriacou, A	en
dc.date.accessioned	2014-06-06T06:50:57Z
dc.date.available	2014-06-06T06:50:57Z
dc.date.issued	2011	en
dc.identifier.issn	10759964	en
dc.identifier.uri	http://dx.doi.org/10.1016/j.anaerobe.2011.03.025	en
dc.identifier.uri	http://62.217.125.90/xmlui/handle/123456789/5240
dc.subject	Beta-glucan	en
dc.subject	Faecal microbiota	en
dc.subject	Polypectomized patients	en
dc.subject.other	acetic acid	en
dc.subject.other	bacterial enzyme	en
dc.subject.other	beta glucan	en
dc.subject.other	beta glucosidase	en
dc.subject.other	beta glucuronidase	en
dc.subject.other	butyric acid	en
dc.subject.other	volatile fatty acid	en
dc.subject.other	abdominal pain	en
dc.subject.other	adult	en
dc.subject.other	article	en
dc.subject.other	bacterial viability	en
dc.subject.other	bacterium identification	en
dc.subject.other	Bacteroides	en
dc.subject.other	barley	en
dc.subject.other	Bifidobacterium	en
dc.subject.other	bloating	en
dc.subject.other	Candida	en
dc.subject.other	carbohydrate analysis	en
dc.subject.other	clinical article	en
dc.subject.other	Clostridium perfringens	en
dc.subject.other	coliform bacterium	en
dc.subject.other	concentration (parameters)	en
dc.subject.other	controlled study	en
dc.subject.other	diet	en
dc.subject.other	Enterococcus	en
dc.subject.other	enzyme activity	en
dc.subject.other	Escherichia coli	en
dc.subject.other	feces analysis	en
dc.subject.other	feces microflora	en
dc.subject.other	female	en
dc.subject.other	food intake	en
dc.subject.other	gastrointestinal symptom	en
dc.subject.other	human	en
dc.subject.other	intestine flora	en
dc.subject.other	Lactobacillus	en
dc.subject.other	male	en
dc.subject.other	moisture	en
dc.subject.other	pH measurement	en
dc.subject.other	pilot study	en
dc.subject.other	polypectomy	en
dc.subject.other	priority journal	en
dc.subject.other	risk reduction	en
dc.subject.other	treatment duration	en
dc.subject.other	Abdominal Pain	en
dc.subject.other	Aged	en
dc.subject.other	Bacteria	en
dc.subject.other	beta-Glucans	en
dc.subject.other	Biota	en
dc.subject.other	Candida	en
dc.subject.other	Carboxylic Acids	en
dc.subject.other	Colonic Polyps	en
dc.subject.other	Colony Count, Microbial	en
dc.subject.other	Diet	en
dc.subject.other	Enzymes	en
dc.subject.other	Feces	en
dc.subject.other	Female	en
dc.subject.other	Hordeum	en
dc.subject.other	Humans	en
dc.subject.other	Hydrogen-Ion Concentration	en
dc.subject.other	Male	en
dc.subject.other	Middle Aged	en
dc.subject.other	Pilot Projects	en
dc.subject.other	Placebos	en
dc.subject.other	Bacteria (microorganisms)	en
dc.subject.other	Bacteroides sp.	en
dc.subject.other	Candida	en
dc.subject.other	Clostridium perfringens	en
dc.subject.other	Embryophyta	en
dc.subject.other	Fungi	en
dc.subject.other	Hordeum	en
dc.title	Impact of beta-glucan on the faecal microbiota of polypectomized patients: A pilot study	en
heal.type	journalArticle	en
heal.identifier.primary	10.1016/j.anaerobe.2011.03.025	en
heal.publicationDate	2011	en
heal.abstract	Beta-glucans are polysaccharides present in the cell walls of higher plants, in the seeds of some cereals, and certain yeasts and fungi also produce them. It is suggested that they exhibit, among many other health benefits, protective effects against carcinogenesis in the colon, but there is not enough human data to support this. The aim of the study was to determine the effect of barley-derived beta-glucan in the gut microbiota of polypectomized patients. Subjects were randomly assigned to consume 125g of bread per day with beta-glucan (3g/d), or without (placebo group), for 3 months. Thirty-three polypectomized men and women (mean age 57.6 years) were recruited into the study, but only 20 completed. Subjects did not consume any probiotics, prebiotics or antibiotics 2 months prior the intervention, or during the study. Stool samples were collected at baseline, on days 30 and 90 of intervention, as well as 2 weeks after the intervention, for enumeration of total aerobes and anaerobes, coliforms, E.coli, enterococci, Bacteroides spp., Clostridium perfringens, bifidobacteria, lactobacilli and Candida spp. Faecal bacterial enzyme activity (beta-glucuronidase and beta-glucosidase), pH, faecal moisture and the concentration of volatile fatty acids in the faeces were measured. Gastrointestinal symptoms were also recorded. Overall, no significant differences were observed in bacterial viable counts between the two feeding groups. Group specific analysis for β-glucan group revealed significantly decreased total coliform counts on the 30th day of the trial compared to the baseline (p=0.041). Clostridium perfringens concentration increased without reaching statistical significance, on the 30th day, while it decreased significantly on the 90th day of the intervention compared to the 30th day (p=0.016). An increase was noted in the molar ratio of acetate on the 90th day of the trial compared to placebo (p=0.018). The molar ratio of butyrate presented a trend to increase on the 30th day, which decreased (p=0.013) on the 90th day and then increase 2 weeks after the intervention (p=0.017) compared to placebo. A decrease was recorded in the β-glucan group in the bloating and abdominal pain score after the 30th day of the intervention (Day 30-37) compared to placebo. During β-glucan administration we did not observe any changes on beta-glucuronidase or beta-glucosidase activity, faecal pH, or on faecal moisture. © 2011 Elsevier Ltd.	en
heal.journalName	Anaerobe	en
dc.identifier.issue	6	en
dc.identifier.volume	17	en
dc.identifier.doi	10.1016/j.anaerobe.2011.03.025	en
dc.identifier.spage	403	en
dc.identifier.epage	406	en